Introduction
============

Gastric cancer is the fourth most common cancer and the second most common cause of cancer-related mortalities ([@b1-ol-0-0-4913]). Delayed diagnosis is the principal cause of increased mortality and morbidity associated with this type of cancer. At the time of diagnosis, only 25% of patients are able to undergo surgical resection. The 5-year survival rate is only 10--15% in individuals with advanced disease ([@b1-ol-0-0-4913]). Therefore, early diagnosis is crucial, especially given that early symptoms (dyspepsia, mild epigastric pain, nausea, and anorexia) are not very specific. Biomarkers including, CEA and CA 19-9, have been tested. However, these biomarkers have a low diagnostic ability to detect gastric cancer ([@b2-ol-0-0-4913]). Therefore, identification of novel biomarkers for the diagnosis and follow-up of gastric cancer is essential.

Platelets play an important and multifaceted role in cancer progression ([@b3-ol-0-0-4913]). Previous findings suggested that platelets accelerate the natural course of cancer by promoting neoangiogenesis, degradation of the extracellular matrix, release of adhesion molecules, and growth factors, thus providing essential components for tumor growth and metastatic spread ([@b4-ol-0-0-4913]). The presence of platelets is increased by proinflammatory cytokines released by cancer cells through the promotion of megakaryocyte proliferation ([@b5-ol-0-0-4913]). Given the relationship between platelet and cancer, platelet-based markers are potential candidates for the diagnosis and follow-up of gastric cancer. Elevated mean platelet volume (MPV) of peripheral blood has been identified in various types of cancer, including hepatocellular carcinoma ([@b6-ol-0-0-4913]), ovarian ([@b7-ol-0-0-4913]), colon ([@b8-ol-0-0-4913]) lung and breast ([@b9-ol-0-0-4913]) cancer. In the present study, we examined whether MPV is suitable as a diagnostic and prognostic marker for the detection of resectable gastric cancer.

Materials and methods
=====================

### Patients

The study was conducted as a retrospective study of patients with gastric cancer who had been referred to the First Affiliated Hospital of Soochow University between January, 2007 and January, 2010. Approval for the study was granted by the Medical Ethics Committees of the First Affiliated Hospital of Soochow University (Jiangsu, China). Patients with hypertension, hematological and renal disease, heart failure, chronic infection, hepatic disorder and other cancer types were excluded from the study. In total, 168 patients with resectable gastric cancer were recruited in this study. Patient characteristics are presented in [Table I](#tI-ol-0-0-4913){ref-type="table"}. The mean age (range) of study patients was 56.5 (31--82) years. The staging of cancer was determined according to the tumor-node-metastasis (TNM) classification, using the American Joint Committee on Cancer (AJCC) recommendations ([@b10-ol-0-0-4913]). The patients were followed regularly for 60 months. Thirty age- and gender-matched healthy individuals were also included in the present study.

### Blood analysis

Peripheral venous blood (5--7 ml) was collected into sterile EDTA tubes. Blood specimens were obtained in the morning between 06:30 and 07:30 a.m. to minimize the impact of circulating hormones (circadian rhythm) on the number and subtype distribution of white blood cells. Haematological parameters were analyzed within 30 min after blood collection using a haematology analyser Sysmex XE-2100 (Sysmex, Kobe, Japan). MPV was thus obtained and used in subsequent analyses.

### Statistical analysis

Statistical analyses were performed using SPSS 19.0 software (SPSS, Inc., Chicago, IL, USA). Measurement data were presented as mean ± standard variation. The association between MPV and clinicopathological features were tested using the Chi-square test. For the analysis of survival data, Kaplan-Meier curves were constructed, and statistical analysis was carried out using the log-rank test. The prognostic analyses were performed as disease-free survival (DFS) and overall survival (OS). OS was defined as the time from the diagnosed date to death from any cause. DFS was defined as the time from the primary operation to the relapse of tumor. The multivariate Cox regression was performed for each outcome parameter, using a backwards elimination technique to derive a potentially suitable set of predictors. P\<0.05 was considered to indicate statistically significant results.

Results
=======

### Pre-operative MPV is higher in patients with gastric cancer patients compared with healthy controls

The mean pre-operative MPV in the study patients was 10.82±1.06, which was significantly higher than that in the healthy individuals (8.37±0.78, p\<0.001; [Fig. 1](#f1-ol-0-0-4913){ref-type="fig"}). This result indicated that MPV is useful in the early diagnosis of gastric cancer.

### Low pre-operative MPV level predicts better outcomes

As shown in [Table I](#tI-ol-0-0-4913){ref-type="table"}, pre-operative MPV levels inversely correlated with clinicopathological parameters, including depth of invasion, lymphonodus metastasis and the AJCC stage.

Median OS for all the patients was 57 months, whereas the median was DFS 27 months ([Fig. 2A](#f2-ol-0-0-4913){ref-type="fig"}).

The patients were separated into two groups according to median pre-operative MPV: low (\<10.51) and high (≥10.51) MPV. The Kaplan-Meier plots showed the association between pre-operative MPV and OS and PFS ([Fig. 2B and C](#f2-ol-0-0-4913){ref-type="fig"}). The OS and PFS rates of high pre-operative MPV were 29.8 and 11.9%, respectively, and were significantly different from corresponding rates in the low pre-operative MPV group (46.7 and 24.3%, respectively, both p\<0.01). This result demonstrated that patients with higher pre-operative MPV had decreased survival rates.

### MPV changes before and after surgery predict improved outcomes

MPV increased significantly 3--4 days following surgery and returned to pre-operation levels one week after the surgery ([Fig. 3A](#f3-ol-0-0-4913){ref-type="fig"}). Furthermore, surgical tumor resection led to a significant decrease in the average MPV one month after surgery ([Fig. 3A](#f3-ol-0-0-4913){ref-type="fig"}).

When individual MPV changes were evaluated, it was observed that a decrease was present in 99 patients and absent in the remaining 69 patients. The Kaplan-Meier plots indicating an association between MPV values and OS are shown in [Fig. 3B](#f3-ol-0-0-4913){ref-type="fig"}. It was evident that OS was improved in patients whose MPV decreased after surgery, compared with those without any change (40.5 vs. 28.9%, p\<0.0037; [Fig. 3B](#f3-ol-0-0-4913){ref-type="fig"}).

### Univariate and multivariate analysis of risk factors for OS and DFS

Univariate and multivariate analyses were performed to identify the risk factors associated with OS and DFS. As shown in [Table II](#tII-ol-0-0-4913){ref-type="table"}, univariate analysis revealed that 5 of 10 risk factors affected OS and DFS. These factors included depth of invasion, lymphonodus metastasis, AJCC stage, pre-operatic MPV, and changes in MPV after surgery. Multivariate analysis further confirmed that depth of invasion, lymphonodus metastasis, AJCC stage, and changes in MPV following surgery were the factors associated with OS. Furthermore, AJCC stage and pre-operative MPV were the prognostic factors for DFS.

Discussion
==========

The involvement of platelets and coagulation factors in hematogenous tumor metastasis are well known. Elevated thrombocytosis and platelet counts are associated with advanced, often metastatic, stages of cancer and to be negative prognostic markers for various types of cancer, including endometrial carcinoma, cervical, ovarian, gastric, and esophageal cancer ([@b11-ol-0-0-4913]).

Platelets participate in multiple steps of hematogenous metastasis. Covered with platelets, circulating cancer cells can transport more easily in the bloodstream and overcome countering effects of immune cells and physical factors such as shear force and mechanical trauma due to passage through microvasculature ([@b12-ol-0-0-4913],[@b13-ol-0-0-4913]). Platelets can also promote tumor growth by increasing angiogenesis via the cytokine vascular endothelial growth factor (VEGF). The platelet content of VEGF is significantly elevated in cancer patients, and there is a direct correlation between the number of circulating platelets and the level of serum VEGF ([@b3-ol-0-0-4913]).

The cancer-promoting effects of platelets are amplified by stimulation of activation and aggregation of platelets caused by proinflammatory cytokines released by cancer cells ([@b4-ol-0-0-4913]). This involves proliferation and differentiation of early progenitor cells such as megakaryocyte progenitors. In addition, malignant cells possess the ability of aggregating platelets through a process known as tumor cell-induced platelet aggregation (TCIPA) ([@b12-ol-0-0-4913]). Therefore, the close involvement of the platelet with metastasizing cancer makes this cell type a promising candidate for early cancer diagnosis and treatment ([@b11-ol-0-0-4913]).

Large platelets are more reactive than their smaller counterparts, and are more likely to aggregate, leading to thrombosis. Large platelets are an independent risk factor for myocardial infarction, as platelet size is a predictor of recurrent myocardial infarction and death ([@b14-ol-0-0-4913]). The MPV tested in our study can be easily evaluated by hematological analyzers, which makes it a convenient marker of platelet functions and activation ([@b3-ol-0-0-4913]). Elevated MPV may indicate a tendency towards thrombosis, as it has been demonstrated for myocardial infarction and cerebrovascular embolus ([@b15-ol-0-0-4913]). Previous studies suggested that MPV is a potential biomarker for the diagnosis and follow-up of types of cancer ([@b6-ol-0-0-4913]--[@b9-ol-0-0-4913]).

Elevated MPV values may be a consequence of systemic inflammatory response ([@b16-ol-0-0-4913]), which is believed to play a critical role in the development and progression of different cancers by promoting cancer cell proliferation and survival, angiogenesis, cancer metastasis and modulating cancer cell response to therapies ([@b3-ol-0-0-4913]). Numerous types of cancer release proinflammatory cytokines, such as interleukin (IL)-1, IL-3, and IL-6, which promote the proliferation of megakaryocytes, resulting in platelet activation and aggregation ([@b4-ol-0-0-4913]). In ovarian cancer, elevated levels of IL-6 in ascites and cyst fluids have been associated with thrombocytosis. Furthermore, administration of recombinant IL-6 has been associated with increased platelet count ([@b5-ol-0-0-4913]). Elevated IL-6 is significantly higher in individuals with gastric cancer, as well as in patients with prostate cancer ([@b17-ol-0-0-4913],[@b18-ol-0-0-4913]).

The close interplay between inflammation, coagulation, and cancer progression ignited intensive studies in this field ([@b4-ol-0-0-4913]). For example, long-term use of non-steroid anti-inflammatory drugs such as aspirin is associated with a reduced risk of esophageal cancer ([@b1-ol-0-0-4913]). Clinical and epidemiological studies demonstrated an association between chronic inflammation and gastric cancer ([@b19-ol-0-0-4913]--[@b21-ol-0-0-4913]). Based on these considerations, we postulated that elevated MPV values in patients with gastric cancer may be a consequence of systemic inflammatory response. Correspondingly, a decrease of MPV values after surgery may be due to a decreased systemic inflammatory response. Therefore, patients whose MPV values did not decrease after surgical resection of the cancer may continue to harbor untamed systemic inflammatory response, leading to an unfavourable prognosis.

In conclusion, the present study indicates an association of the pre-operative MPV level and changes between pre- and post-operative levels with the diagnosis and prognosis of gastric cancer. Although MPV is also a non-specific marker, this non-invasive, convenient and inexpensive biomarker may be a complement to the present biomarkers, and a benefit to the early detection and prognosis evaluation of gastric cancer.
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###### 

Relationship between pre-operative MPV and demographic and clinical parameters.

  Parameters                              No. of patients   Low MPV (\<10.51), no. of patients   High MPV (≥10.51), no. of patients   χ^2^      P-value
  --------------------------------------- ----------------- ------------------------------------ ------------------------------------ --------- ------------------------------------------------------
  Gender                                                                                                                                        
    Male                                  116               62                                   54                                   1.7825    0.1818
    Female                                  52              22                                   30                                             
  Age (years)                                                                                                                                   
    \<65                                  96                45                                   51                                   0.8750    0.3496
    ≥65                                     72              39                                   33                                             
  Tumor size (cm)                                                                                                                               
    \<5                                   108               51                                   57                                   0.9333    0.3340
    ≥5                                      60              33                                   27                                             
  Lauren type                                                                                                                                   
    Intestinal                              97              50                                   47                                   0.2195    0.6394
    Diffuse                                 71              34                                   37                                             
  Depth of invasion                                                                                                                             
    T1, T2                                  66              15                                   51                                   32.3422   \<0.001^[a](#tfn1-ol-0-0-4913){ref-type="table-fn"}^
    T3, T4                                102               69                                   33                                             
  Lymph node metastases                                                                                                                         
    N0, N1                                  54              12                                   42                                   24.5614   \<0.001^[a](#tfn1-ol-0-0-4913){ref-type="table-fn"}^
    N2, N3                                114               72                                   42                                             
  Degree of differentiation                                                                                                                     
    Highly differentiated                   50              23                                   27                                   0.4556    0.4997
    Moderately or poorly differentiated   118               61                                   57                                             
  AJCC stage                                                                                                                                    
    I, II                                   57              12                                   45                                   28.9161   \<0.001^[a](#tfn1-ol-0-0-4913){ref-type="table-fn"}^
    III, IV                               111               72                                   39                                             

P\<0.05, statistically significant. MPV, mean platelet volume; AJCC, American Joint Committee on Cancer.

###### 

Univariate and multivariate analysis of risk factors for OS and DFS.

                                                 OS                  DFS                                                                                 
  ---------------------------------------------- ------------------- ------- ------------------- ------- ------------------- ------- ------------------- -------
  Gender                                                                                                                                                 
    Male or female                               0.75 (0.46--1.72)   0.806   --                  --      0.81 (0.44--1.60)   0.835   --                  --
  Age (years)                                                                                                                                            
    \<65 or ≥65                                  1.16 (0.69--1.82)   0.629   --                  --      1.22 (0.68--2.03)   0.825   --                  --
  Tumor size (cm)                                                                                                                                        
    \<5 or ≥5                                    1.37 (0.68--2.73)   0.227   --                  --      1.27 (0.65--2.42)   0.237   --                  --
  Lauren type                                                                                                                                            
    Intestinal or diffuse                        1.29 (0.73--2.25)   0.605   --                  --      1.89 (1.33--2.40)   0.454   --                  --
  Depth of invasion                                                                                                                                      
    T1, T2 or T3, T4                             2.61 (1.53--3.02)   0.036   2.53 (1.64--3.05)   0.028   2.60 (1.42--3.31)   0.040   --                  --
  Degree of differentiation                                                                                                                              
    Highly or moderately/poorly differentiated   1.46 (0.72--1.85)   0.722   --                  --      1.38 (0.74--1.91)   0.757   --                  --
  Lymph node metastases                                                                                                                                  
    N0, N1 or N2, N3                             3.54 (2.47--6.80)   0.022   3.64 (2.49--6.85)   0.021   2.92 (1.86--4.53)   0.037   --                  --
  AJCC stage                                                                                                                                             
    I, II or III, IV                             4.82 (3.15--7.89)   0.002   4.32 (2.70--6.83)   0.003   4.39 (2.98--6.97)   0.002   4.25 (2.80--6.51)   0.003
  MPV                                                                                                                                                    
    Low (\<10.51) or High (≥10.51)               2.56 (1.42--3.37)   0.004   --                  --      2.78 (1.67--3.78)   0.003   2.41 (1.36--3.52)   0.001
  Changes in MPV after operation                                                                                                                         
    Decreased or not decreased                   3.52 (2.27--6.04)   0.001   3.57 (2.49--5.92)   0.001   3.55 (2.16--5.83)   0.001   --                  --

OS, overall survival; DFS, disease-free survival; OR, odds ratio; CI, confidence interval; AJCC, American Joint Committee on Cancer; MPV, mean platelet volume.
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